Dr Reddy's Laboratories (FRA:RDDA) Cyclically Adjusted Revenue per Share: €2.94 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:RDDA Dr Reddy's Laboratories Ltd FRA:RDDA
92 GF Score
Price €10.80
GF Value €12.58
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share?

Dr Reddy's Laboratories FRA:RDDA -0.92% 92 Cyclically Adjusted Revenue per Share is €2.94 as of Mar. 2026. GuruFocus rates FRA:RDDA with a GF Score™ of 92/100 and a GF Value™ of €12.58 (Modestly Undervalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Dr Reddy's Laboratories's adjusted revenue per share for the three months ended in Mar. 2026 was €0.840. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €2.94 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Dr Reddy's Laboratories's average Cyclically Adjusted Revenue Growth Rate was 8.20% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 7.40% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 7.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Dr Reddy's Laboratories was 18.80% per year. The lowest was 5.80% per year. And the median was 8.40% per year.

As of today (2026-07-22), Dr Reddy's Laboratories's current stock price is €10.80. Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €2.94. Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio of today is 3.67.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dr Reddy's Laboratories was 5.17. The lowest was 2.27. And the median was 3.85.


Dr Reddy's Laboratories  (FRA:RDDA) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=10.80/2.94
=3.67

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Dr Reddy's Laboratories was 5.17. The lowest was 2.27. And the median was 3.85.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Related Terms


Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Dr Reddy's Laboratories's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Chart

Dr Reddy's Laboratories Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.78 2.91 3.08 3.15 2.94

Dr Reddy's Laboratories Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.15 2.97 2.95 2.91 2.94

FRA:RDDA vs ZTS, UTHR: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Dr Reddy's Laboratories Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Dr Reddy's Laboratories's Cyclically Adjusted PS Ratio falls into.


FRA:RDDA
92GF Score
Dr Reddy's Laboratories Ltd FRA:RDDA
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dr Reddy's Laboratories Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Dr Reddy's Laboratories's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.84/164.2724*164.2724
=0.840

Current CPI (Mar. 2026) = 164.2724.

Dr Reddy's Laboratories Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.504 105.961 0.781
201609 0.577 105.961 0.895
201612 0.624 105.196 0.974
201703 0.609 105.196 0.951
201706 0.552 107.109 0.847
201709 0.556 109.021 0.838
201712 0.603 109.404 0.905
201803 0.530 109.786 0.793
201806 0.566 111.317 0.835
201809 0.542 115.142 0.773
201812 0.575 115.142 0.820
201903 0.616 118.202 0.856
201906 0.590 120.880 0.802
201909 0.737 123.175 0.983
201912 0.669 126.235 0.871
202003 0.648 124.705 0.854
202006 0.624 127.000 0.807
202009 0.680 130.118 0.858
202012 0.662 130.889 0.831
202103 0.656 131.771 0.818
202106 0.668 134.084 0.818
202109 0.800 135.847 0.967
202112 0.751 138.161 0.893
202203 0.778 138.822 0.921
202206 0.760 142.347 0.877
202209 0.954 144.661 1.083
202212 0.931 145.763 1.049
202303 0.859 146.865 0.961
202306 0.908 150.280 0.993
202309 0.932 151.492 1.011
202312 0.953 152.924 1.024
202403 0.941 153.035 1.010
202406 1.024 155.789 1.080
202409 1.033 157.882 1.075
202412 1.126 158.323 1.168
202503 1.090 157.552 1.136
202506 1.036 159.755 1.065
202509 1.019 162.289 1.031
202512 0.993 163.281 0.999
202603 0.840 164.272 0.840

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €2.94 mean?
Dr Reddy's Laboratories (FRA:RDDA) has a Cyclically Adjusted Revenue per Share of €2.94 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Dr Reddy's Laboratories and its competitors.
Is Dr Reddy's Laboratories' Cyclically Adjusted Revenue per Share too high?
Dr Reddy's Laboratories' current Cyclically Adjusted Revenue per Share is €2.94. Overall, Dr Reddy's Laboratories has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Dr Reddy's Laboratories' Cyclically Adjusted Revenue per Share compare to ZTS and UTHR?
Dr Reddy's Laboratories' Cyclically Adjusted Revenue per Share of €2.94 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Dr Reddy's Laboratories and its competitors. Dr Reddy's Laboratories's current Cyclically Adjusted Revenue per Share is €2.94. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dr Reddy's Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Dr Reddy's Laboratories (FRA:RDDA) is currently considered Modestly Undervalued. The stock's GF Value™ is €12.58, compared to a current price of €10.80 — trading 14.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €2.94. Dr Reddy's Laboratories' overall GF Score™ is 92/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Dr Reddy's Laboratories (FRA:RDDA), the current Cyclically Adjusted Revenue per Share is €2.94 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dr Reddy's Laboratories (FRA:RDDA) Overvalued in 2026?

Based on GuruFocus' analysis, Dr Reddy's Laboratories stock appears to be undervalued. The current stock price of €10.80 is trading 14.1% below its estimated GF Value™ of €12.58. GuruFocus considers Dr Reddy's Laboratories to be Modestly Undervalued.

Key valuation signals for FRA:RDDA:

  • Cyclically Adjusted Revenue per Share: €2.94
  • GF Value™: €12.58 vs. price of €10.80 (14.1% below fair value)
  • GF Score™: 92/100 with 3 warning signs

No single metric tells the full story. See the FRA:RDDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Dr Reddy's Laboratories Business Description

Address 8-2-337, Road No. 3, Banjara Hills, Hyderabad, TG, IND, 500 034
Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly 40% of its generics sales, with other key markets being India (20%) and Europe (20%). Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.
92GF Score

Get the complete analysis for FRA:RDDA

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€10.80
Price
€12.58
GF Value